Skip To Main Content

Tumor Types

Investigational Therapies

These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Showing 84 out of 84 results

Phase III

Breast

  • Giredestrant
    (SERD)

    (GDC-9545, RG6171)
    Breast
  • Inavolisib
    (PI3K alpha inhibitor)

    (GDC-0077, RG6114)
    Breast
  • Ipatasertib
    (AKT inhibitor)

    (RG7440, GDC-008)a
    Breast

Gastrointestinal

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)b
    Gastrointestinal
  • Tiragolumab
    (anti-TIGIT)

    (MTIG7192A, RG6058)
    Gastrointestinal
    Lung

Hematology

  • Glofitamab
    (anti-CD20 x CD3)

    (RG6026)
    Hematology
  • Mosunetuzumab
    (anti-CD20 x CD3)

    (RG7828)
    Hematology
  • Venetoclax
    (BCL-2 inhibitor)

    (RG7601)c
    Hematology

Lung

Phase II

Gastrointestinal

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)b
    Gastrointestinal
    Hematology
  • Tobemstomig
    (PD-1 x LAG3)

    (RG6139)
    Gastrointestinal
    Melanoma

Hematology

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)b
    Gastrointestinal
    Hematology
  • Cevostamab
    (anti-FcRH5 x CD3)

    (RG6160)
    Hematology
  • Glofitamab
    (anti-CD20 x CD3)

    (RG6026)
    Hematology
  • Mosunetuzumab
    (anti-CD20 x CD3)

    (RG7828)
    Hematology
  • Venetoclax
    (BCL-2 inhibitor)

    (ABT-199, RG7601)c
    Hematology

Lung

Melanoma

  • Tobemstomig
    (PD-1 x LAG3)

    (RG6139)
    Gastrointestinal
    Melanoma

Solid Tumor

  • Camonsertib (ATR inhibitor)

    (RG6526)d
    Solid Tumor

Phase I

Brain

Breast

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)b
    Breast
    Gastrointestinal
    Genitourinary
    Gynecologic
    Head Neck
    Hematology
    Solid Tumor
  • Inavolisib
    (PI3K alpha inhibitor)

    (GDC-0077, RG6114)
    Breast
    Solid Tumor
  • New molecular entity (NME)

    (RG6411)
    Breast
    Gastrointestinal
    Genitourinary
    Gynecologic
    Head Neck
    Lung
    Melanoma
    Solid Tumor
  • Runimotamab
    (HER2 x CD3)

    (RG6194)
    Breast
    Gastrointestinal
    Solid Tumor

Gastrointestinal

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)b
    Breast
    Gastrointestinal
    Genitourinary
    Gynecologic
    Head Neck
    Hematology
    Solid Tumor
  • Cibisatamab
    (CEA x CD3)

    (RG7802)
    Gastrointestinal
  • Divarasib
    (KRAS G12C inhibitor)

    (RG6330)
    Gastrointestinal
    Lung
    Solid Tumor
  • FAP x 4-1BBL

    (RG7827)
    Gastrointestinal
  • New molecular entity (NME)

    (RG6286)
    Gastrointestinal
  • New molecular entity (NME)

    (RG6411)
    Breast
    Gastrointestinal
    Genitourinary
    Gynecologic
    Head Neck
    Lung
    Melanoma
    Solid Tumor
  • Runimotamab
    (HER2 x CD3)

    (RG6194)
    Breast
    Gastrointestinal
    Solid Tumor
  • Tiragolumab
    (anti-TIGIT MAb)

    (RG6058)
    Gastrointestinal
  • Tobemstomig
    (PD-1 x LAG3)

    (RG6139)
    Gastrointestinal
    Lung
    Melanoma
    Solid Tumor

Genitourinary

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)b
    Breast
    Gastrointestinal
    Genitourinary
    Gynecologic
    Head Neck
    Hematology
    Solid Tumor
  • New molecular entity (NME)

    (RG6411)
    Breast
    Gastrointestinal
    Genitourinary
    Gynecologic
    Head Neck
    Lung
    Melanoma
    Solid Tumor

Gynecologic

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)b
    Breast
    Gastrointestinal
    Genitourinary
    Gynecologic
    Head Neck
    Hematology
    Solid Tumor
  • New molecular entity (NME)

    (RG6411)
    Breast
    Gastrointestinal
    Genitourinary
    Gynecologic
    Head Neck
    Lung
    Melanoma
    Solid Tumor
  • SPYK04

    (CHU)f
    Gynecologic
    Lung
    Solid Tumor

Head Neck

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)b
    Breast
    Gastrointestinal
    Genitourinary
    Gynecologic
    Head Neck
    Hematology
    Solid Tumor
  • New molecular entity (NME)

    (RG6411)
    Breast
    Gastrointestinal
    Genitourinary
    Gynecologic
    Head Neck
    Lung
    Melanoma
    Solid Tumor
  • SHP2i
    (SHP2 inhibitor)

    (RG6433)e
    Head Neck
    Lung
    Melanoma
    Solid Tumor

Hematology

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)b
    Breast
    Gastrointestinal
    Genitourinary
    Gynecologic
    Head Neck
    Hematology
    Solid Tumor
  • CD19 x CD28

    (RG6333)
    Hematology
  • Cevostamab
    (anti-FcRH5 x CD3)

    (RG6160)
    Hematology
  • Englumafusp alfa
    (CD19 x 4-1BBL)

    (RG6076)
    Hematology
  • Forimtamig
    (GPRC5D x CD3)

    (RG6234)
    Hematology
  • Glofitamab
    (anti-CD20 x CD3)

    (RG6026)
    Hematology
  • IL15/IL15Ra-Fc

    (RG6323)g
    Hematology
    Solid Tumor
  • Mosunetuzumab
    (anti-CD20 x CD3)

    (RG7828)
    Hematology
  • P-BCMA-ALLO1

    (RG6538)h
    Hematology

Lung

  • DLL3 x CD3 x CD137

    (RG6524)
    Lung
    Solid Tumor
  • Divarasib
    (KRAS G12C inhibitor)

    (RG6330)
    Gastrointestinal
    Lung
    Solid Tumor
  • New molecular entity (NME)

    (RG6411)
    Breast
    Gastrointestinal
    Genitourinary
    Gynecologic
    Head Neck
    Lung
    Melanoma
    Solid Tumor
  • SHP2i
    (SHP2 inhibitor)

    (RG6433)e
    Head Neck
    Lung
    Melanoma
    Solid Tumor
  • SPYK04

    (CHU)f
    Gynecologic
    Lung
    Solid Tumor
  • Tobemstomig
    (PD-1 x LAG3)

    (RG6139)
    Gastrointestinal
    Lung
    Melanoma
    Solid Tumor

Melanoma

  • BRAF inhibitor (3)

    (RG6344)
    Melanoma
    Solid Tumor
  • Belvarafenib
    (pan-RAF inhibitor)

    (RG6185)
    Melanoma
    Solid Tumor
  • New molecular entity (NME)

    (RG6411)
    Breast
    Gastrointestinal
    Genitourinary
    Gynecologic
    Head Neck
    Lung
    Melanoma
    Solid Tumor
  • SHP2i
    (SHP2 inhibitor)

    (RG6433)e
    Head Neck
    Lung
    Melanoma
    Solid Tumor
  • Tobemstomig
    (PD-1 x LAG3)

    (RG6139)
    Gastrointestinal
    Lung
    Melanoma
    Solid Tumor

Solid Tumor

  • Atezolizumab
    (anti-PD-L1 MAb)

    (RG7446)b
    Breast
    Gastrointestinal
    Genitourinary
    Gynecologic
    Head Neck
    Hematology
    Solid Tumor
  • BRAF inhibitor (3)

    (RG6344)
    Melanoma
    Solid Tumor
  • Belvarafenib
    (pan-RAF inhibitor)

    (RG6185)
    Melanoma
    Solid Tumor
  • Camonsertib (ATR inhibitor)

    (RG6526)d
    Solid Tumor
  • Cobimetinib (MEK inhibitor)

    N/A
    Solid Tumor
  • DLL3 x CD3 x CD137

    (RG6524)
    Lung
    Solid Tumor
  • Divarasib
    (KRAS G12C inhibitor)

    (RG6330)
    Gastrointestinal
    Lung
    Solid Tumor
  • Eciskafusp alfa
    (PD-1 x IL2v)

    (RG6279)
    Solid Tumor
  • FAP-CD40

    (RG6189)
    Solid Tumor
  • IL15/IL15Ra-Fc

    (RG6323)g
    Hematology
    Solid Tumor
  • Inavolisib
    (PI3K alpha inhibitor)

    (GDC-0077, RG6114)
    Breast
    Solid Tumor
  • LUNA18

    (CHU)f
    Solid Tumor
  • New molecular entity (NME)

    (RG6411)
    Breast
    Gastrointestinal
    Genitourinary
    Gynecologic
    Head Neck
    Lung
    Melanoma
    Solid Tumor
  • Runimotamab
    (HER2 x CD3)

    (RG6194)
    Breast
    Gastrointestinal
    Solid Tumor
  • SHP2i
    (SHP2 inhibitor)

    (RG6433)e
    Head Neck
    Lung
    Melanoma
    Solid Tumor
  • SPYK04

    (CHU)f
    Gynecologic
    Lung
    Solid Tumor
  • Tobemstomig
    (PD-1 x LAG3)

    (RG6139)
    Gastrointestinal
    Lung
    Melanoma
    Solid Tumor

No results were found


aDeveloped in collaboration with Array Biopharma. bDeveloped in collaboration with Exelixis. cJoint project with AbbVie. dManaged by Repare Therapeutics. eDeveloped in collaboration with Relay Therapeutics. fDeveloped in collaboration with Chugai. gDeveloped in collaboration with Xencor. hManaged by Poseida Therapeutics.
Current as of May 10, 2023. The trial information is taken from ClinicalTrials.gov.

    • Roche. 2023 Q1 results. April 26, 2023. Accessed May 10, 2023. https://assets.cwp.roche.com/f/126832/x/469b6bc1c5/irp230426-a.pdf

      Roche. 2023 Q1 results. April 26, 2023. Accessed May 10, 2023. https://assets.cwp.roche.com/f/126832/x/469b6bc1c5/irp230426-a.pdf